Markets Stocks Economy Crypto Earnings Banking Energy
Home› Stocks› Feature
Stocks · Exclusive

Ellipses Pharma weighs London listing via Wolfram Resources SPAC deal

Ellipses Pharma weighs London listing via Wolfram Resources SPAC deal
Stocks · 2026
Photo · Marcus Devlin for Daily Digest Invest
By Marcus Devlin Equities Correspondent Nov 18, 2026 4 min read

British cancer drug developer Ellipses Pharma is exploring a return to the public markets through a deal with a London-listed special purpose acquisition company (SPAC), according to reports. The company is considering a reverse takeover of Wolfram Resources, a move that could value Ellipses at between £450 million and £500 million.

A reverse takeover is a route to listing that involves a private company merging with an already-listed shell company, allowing it to go public without the lengthy and costly process of a traditional initial public offering (IPO). For Ellipses, this would mean gaining a listing on the London Stock Exchange by folding into Wolfram Resources, which currently has no operating business.

What is Ellipses Pharma?

Ellipses Pharma is a clinical-stage biotechnology company focused on developing cancer treatments. The company's pipeline includes experimental drugs aimed at various solid tumors, and it has been working to advance these candidates through clinical trials. Like many biotech firms, Ellipses has yet to generate significant revenue, as its value is tied to the potential success of its drug candidates.

The company's move to go public comes at a time when the biotech sector is showing signs of renewed investor interest. Recent months have seen a handful of biotech IPOs and listings, including Windward Bio's $175 million IPO, which signaled that the market for biotech listings is waking up. However, not all companies have found the timing right; LEO Pharma's IPO plans slipped as its owners said the market was not ready.

Why a SPAC deal?

SPACs, also known as blank-check companies, raise money through an IPO with the sole purpose of acquiring a private company and taking it public. For a company like Ellipses, a SPAC merger can offer a faster and more flexible path to listing, especially when traditional IPO markets are volatile or uncertain.

Wolfram Resources, the SPAC in question, has been listed in London and is seeking a merger target. By merging with Wolfram, Ellipses would effectively become the listed entity, with Wolfram's existing cash and listing status providing the platform for Ellipses to trade publicly.

This approach is not without its challenges. SPAC deals have faced increased scrutiny from regulators and investors in recent years, and the structure can be complex. However, for a company with a promising pipeline but no revenue, a SPAC merger can provide access to capital and a public currency for future fundraising.

What it means for investors

For everyday investors, the news is a reminder that there are multiple ways for companies to go public, and each carries its own risks and rewards. A SPAC merger can be an opportunity to invest in a company at an early stage, but it also comes with higher uncertainty compared to established, profitable businesses.

Investors considering any biotech investment should be aware that drug development is a high-risk, high-reward endeavor. Clinical trials can fail, regulatory approvals are uncertain, and even successful drugs take years to reach the market. The valuation of £450-500 million reflects the market's assessment of Ellipses' potential, but that potential is far from guaranteed.

The London listing would give UK investors a chance to participate in the company's journey, but it also means they should be prepared for volatility. Biotech stocks are known for sharp moves on trial results and regulatory news.

For the broader market, this deal could be a positive sign for London's listing environment, which has seen a slowdown in new issues in recent years. A successful SPAC merger could encourage other private companies to consider similar routes, potentially boosting the exchange's appeal.

However, investors should also note that the deal is still under consideration. Reports indicate that Ellipses is "weighing" the reverse takeover, meaning terms could change or the deal could fall through. As with any potential transaction, nothing is certain until it is completed.

In the meantime, those interested in the biotech sector might also watch other developments, such as CG Oncology's bladder cancer data and the broader trend of AI biotech startups attracting investment in London. These stories highlight the dynamic nature of the biotech investment landscape.

Ultimately, the Ellipses-Wolfram deal is a reminder that the path to public markets is evolving, and investors should stay informed about the structures and risks involved.

More from this story

Next article · Don't miss

Target's turnaround gains momentum with third straight strong quarter

Target reported another strong quarter, its third in a row, and raised its full-year sales outlook to around 6% growth. The results suggest the retailer is winning back shoppers despite cautious consumer spending.

Read the story →
Target's turnaround gains momentum with third straight strong quarter